Johnson & Johnson Analyst Ratings
AbbVie Analyst Ratings
BMO Capital Adjusts Price Target on Merck to $150 From $148
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Morgan Stanley Keeps Their Hold Rating on Abbott Laboratories (ABT)
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating
Jefferies Adjusts Price Target on Amgen to $380 From $375
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Nephron Adjusts Price Target on Abbott Laboratories to $110 From $115
Maintained Buy Rating for Abbott Laboratories on Strong Financials and Growth Prospects
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
Buy Rating Affirmed for Abbott Laboratories Amid Strong Financials and Growth Potential
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $167, Maintains Equalweight Rating
Johnson & Johnson Analyst Ratings
Stifel Raises Johnson & Johnson's Price Target to $160 From $155